Scarica l'app Stockscreener
23.67
0.13%
-0.03
Precedente Chiudi:
$23.70
Aprire:
$24.06
Volume 24 ore:
303.08K
Relative Volume:
1.19
Capitalizzazione di mercato:
$700.56M
Reddito:
$4.12M
Utile/perdita netta:
$-56.68M
Rapporto P/E:
-4.2703
EPS:
-5.5429
Flusso di cassa netto:
$-51.44M
1 W Prestazione:
-3.35%
1M Prestazione:
+9.28%
6M Prestazione:
-17.03%
1 anno Prestazione:
-1.25%
Intervallo 1D:
$23.37
$24.83
Intervallo di 1 settimana:
$22.77
$25.27
Portata 52W:
$18.34
$33.77
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Nome
Dianthus Therapeutics Inc
Settore
Industria
Telefono
857-201-2700
Indirizzo
300 TECHNOLOGY SQUARE, CAMBRIDGE
Confronta DNTH con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
23.67 | 700.56M | 4.12M | -56.68M | -51.44M | -5.5429 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-20 | Iniziato | TD Cowen | Buy |
| 2024-10-03 | Iniziato | Oppenheimer | Outperform |
| 2024-07-26 | Iniziato | Robert W. Baird | Outperform |
| 2024-06-27 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-05-16 | Iniziato | H.C. Wainwright | Buy |
| 2024-02-15 | Iniziato | Stifel | Buy |
| 2023-12-26 | Iniziato | Jefferies | Buy |
| 2023-11-22 | Iniziato | Wedbush | Outperform |
| 2023-10-30 | Iniziato | Guggenheim | Buy |
| 2023-09-28 | Iniziato | Raymond James | Outperform |
| 2022-08-25 | Downgrade | Goldman | Buy → Neutral |
| 2022-01-06 | Aggiornamento | Goldman | Neutral → Buy |
| 2021-08-20 | Ripresa | Goldman | Neutral |
| 2021-08-03 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-07-22 | Reiterato | B. Riley Securities | Buy |
| 2021-06-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-05-18 | Iniziato | B. Riley Securities | Buy |
| 2021-01-07 | Iniziato | Mizuho | Buy |
| 2020-06-08 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-03-25 | Downgrade | Goldman | Buy → Neutral |
| 2019-03-15 | Iniziato | Raymond James | Outperform |
Mostra tutto
Dianthus Therapeutics Inc Borsa (DNTH) Ultime notizie
Brokerages Set Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Target Price at $46.83 - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Rating of “Buy” by Analysts - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) Trading 8% HigherShould You Buy? - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Short Interest Update - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Purchased by SG Americas Securities LLC - Defense World
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Short Interest Up 6.0% in January - MarketBeat
Octagon Capital Advisors LP Increases Stake in Dianthus Therapeu - GuruFocus.com
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Sees Significant Increase in Short Interest - Defense World
Dianthus Therapeutics to Webcast Presentations at Two Investor Conferences - The Manila Times
Exclusive: Dianthus Therapeutics Reveals Next-Gen Autoimmune Pipeline at Elite Investor Summits - StockTitan
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 4.6%Here's Why - MarketBeat
Equities Analysts Issue Forecasts for DNTH FY2025 Earnings - Defense World
Cantor Fitzgerald Comments on DNTH FY2025 Earnings - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Average Rating of “Buy” by Analysts - Defense World
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Sees Significant Growth in Short Interest - MarketBeat
A Dive Into Dianthus Therapeutics: Little To Move The Stock (NASDAQ:DNTH) - Seeking Alpha
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 5.5%Here's Why - MarketBeat
Barclays PLC Purchases 33,185 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Barclays PLC Acquires 33,185 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Dianthus Therapeutics to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Dianthus Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 6.8%Should You Sell? - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Up 7.8%Here's What Happened - MarketBeat
Jane Street Group LLC Takes $556,000 Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Stake Trimmed by Geode Capital Management LLC - Defense World
Barclays PLC Boosts Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Stock Position Raised by Barclays PLC - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Average Rating of “Buy” by Brokerages - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) Shares Down 2.5%Here's Why - MarketBeat
State Street Corp Increases Stock Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
State Street Corp Increases Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
TD Cowen Initiates Coverage on Dianthus Therapeutics (NASDAQ:DNTH) - Defense World
Forecasting The Future: 5 Analyst Projections For Dianthus Therapeutics - Benzinga
Dianthus Therapeutics (NASDAQ:DNTH) Now Covered by TD Cowen - MarketBeat
Wellington Management Group LLP Invests $1.47 Million in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Upgraded at Raymond James - Defense World
Raymond James Upgrades Dianthus Therapeutics (NASDAQ:DNTH) to Moderate Buy - MarketBeat
Charles Schwab Investment Management Inc. Increases Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Charles Schwab Investment Management Inc. Boosts Stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
MetLife Investment Management LLC Purchases 7,854 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Point72 Asset Management L.P. Buys 263,500 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics Inc Azioni (DNTH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):